MOTS-c

MOTS-c is a mitochondrial-derived peptide, sixteen amino acids long, encoded not in the cell nucleus but within the 12S rRNA region of mitochondrial DNA. It was first described in 2015, reported to support metabolic balance and, in mice, to blunt the obesity and insulin resistance that a rich diet produces [1]. Blood levels climb after physical activity, and its biology runs alongside what exercise does to metabolism — which is how it came to be marketed as an exercise mimetic.

The marketing has outrun the evidence by a considerable distance. It holds no FDA approval for anything, and nobody has ever published a randomized human trial of it for weight loss — something we checked against PubMed directly rather than assuming. Every striking result about metabolism or exercise capacity traces back to mice and cell culture. What human studies exist track it in the bloodstream as a marker of exercise or of aging; not one gives it as a drug. Those are different studies answering different questions, and the gap between them is where the sales copy lives.

A short open reading frame inside the mitochondrial 12S ribosomal RNA gene is what it gets translated from, which sets it apart from the overwhelming majority of proteins, encoded as those are in nuclear DNA. Once made, it can act locally within the mitochondria and, under metabolic stress, move into the nucleus, and the proposal there is that it takes a hand in regulating genes that govern metabolism and antioxidant defense [2].

Mouse work has shown it helping regulate fat-tissue homeostasis and guarding against the metabolic damage that follows removal of the ovaries [4]. A 2021 Nature Communications paper cast it as a mitochondrially encoded regulator, switched on by exercise, of age-related physical decline and muscle upkeep — its headline findings, once again, produced in mice [3]. This is real mitochondrial biology, actively studied. What it is not is a mechanism anybody has demonstrated takes weight off humans, and the two should not be allowed to blur.

The 2015 Cell Metabolism paper that started this reported improved insulin sensitivity and protection against diet-induced obesity in mice [1]. Later mouse work extended it to fat-tissue regulation [4], and the 2021 study tied it to exercise capacity and muscle maintenance, again in mice [3]. These three are what get cited to sell it online, and all three are rodent studies.

The human literature exists and answers something else entirely. One 2021 study put people through a single endurance session and measured mitochondrial-derived peptides rising in the blood afterward, this one included [5]. That establishes it as a biomarker responding to exercise. It does not test whether giving it to someone causes weight loss, and it should not be cited as though it did. Search PubMed for a human randomized trial using it to treat obesity and you come back empty-handed. Reviews of mitochondrial-derived peptides in aging treat it as a promising research target whose levels fall with age, while stating plainly that the therapeutic case in humans is unproven [6].

No human dose has been established or clinically validated. Since no human randomized trial has tested it for weight loss or metabolic benefit, no dose has been shown safe or effective in people, and the figures circulating on vendor sites and forums have nothing behind them. We deliberately publish no dosing protocol here: printing one would imply a validated regimen exists, and none does.

It carries no FDA approval for any human indication and does not appear in DailyMed. What sells online is almost all research chemical, stamped with a not-for-human-consumption label — the disclaimer that lets a vendor ship a vial without answering to the rules on marketing a drug. Nothing is regulated here, so no agency verifies what is in the vial — whether it is the right molecule, how pure, how sterile, or at what dose. Injecting something unverified brings real risk — contaminants, infection, a dose nobody has measured — and no proven human benefit sits on the other side of that ledger.

The clinics in our register that offer it prescribe through a licensed clinician rather than shipping a research-use vial, and that oversight is a material difference from the gray market — sourcing is accountable and someone qualified is watching. It does not alter the evidence. Even with a doctor involved, no human trial has shown it takes weight off, so treat it as the unproven off-label compounded peptide it is and raise the absence of efficacy data with your prescriber before you start rather than after.